Two ocular manifestations of Rheumatoid Arthritis: episcleritis and scleritis
Keywords:
ocular manifestations, rheumatoid arthritis, episcleritis, scleritisAbstract
Rheumatoid arthritis is a systemic inflammatory disorderthat affects the joints, which can have several
extra-articular manifestations, including inflammatory eye
disease. To provide an overview of the diagnosis and
treatment of two ocular manifestations of rheumatoid
arthritis: episcleritis and scleritis, including an update on
treatment prospects. Ocular manifestations, including
episcleritis, scleritis, peripheral ulcerative keratitis, and
dry eye disease, can be found in up to 39% of
rheumatoid arthritis patients. Although there is no
consensus or guidelines, many options issued from
rheumatology practice will be available for the treatment
of refractory scleritis, once the infectious causes have
been ruled out, allowing rapid control of inflammation,
and avoiding both structural damage to the eye and
complications from long-term steroid use.
Downloads
References
Vignesh APP, Srinivasan R. Ocular manifestations of rheumatoid arthritis and their correlation with anti-cyclic citrullinated peptide antibodies. Clin. Ophthalmol [Internet]. 2015 [Acceso: 28/07/2021]; 9:393-7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348132/
Itty S, Pulido JS, Bakri SJ, Baratz KH. Matteson EL, Hodge DO. Anti-Cyclic Citrullinated Peptide, Rheumatoid Factor, and Ocular Symptoms Typical of Rheumatoid Arthritis. Trans. Am. Ophthalmol. Soc [Internet]. 2008 [Acceso: 28/07/2021]; 106:75-81. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646447/
Caimmi C, Crowson CS, Smith WM, Matteson EL, Makol A. Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era. J. Rheumatol [Internet]. 2018 [Acceso: 28/07/2021]; 45(5):595-603. Disponible en: https://www.jrheum.org/content/jrheum/45/5/595.full.pdf
Watson PG, Hayreh SS. Scleritis and episcleritis. Br. J. Ophthalmol [Internet]. 1976 [Acceso: 28/07/2021]; 60:163-191. Disponible en: https://bjo.bmj.com/content/bjophthalmol/60/3/163.full.pdf
Lavric A, Gonzalez-Lopez JJ, Majumder PD, Bansal N, Biswas J, Pavesio C, Agrawal R. Posterior Scleritis: Analysis of Epidemiology, Clinical Factors, and Risk of Recurrence in a Cohort of 114 Patients. Ocul. Immunol. Inflamm [Internet]. 2016 [Acceso: 28/07/2021]; 24: 6-15. Disponible en: https://doi.org/10.3109/09273948.2015.1005240
Canamary AM, Takahashi WY, Sallum JMF. Autoimmune retinopathy: A Review. Int J Retin Vitr [Internet]. 2018 [Acceso: 28/07/2021]; 4(1). Disponible en: https://doi.org/10.1186/s40942-017-0104-9
Yoshida A, Watanabe M, Okubo A, Kawashima H. Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis). J. Ophthalmol [Internet]. 2019 [Acceso: 28/07/2021]; 63:417-24. Disponible en: https://link.springer.com/article/10.1007/s10384-019-00674-7
Pattern of Scleritis in an Egyptian Cohort. Ocul. Immunol. Inflamm [Internet]. 2019 [Acceso: 28/07/2021]; 27:890-6. Disponible en: https://doi.org/10.1080/09273948.2018.1544372
Yang P, Ye Z, Tang J, Du L, Zhou Q, Qi J, et al. Clinical Features and Complications of Scleritis in Chinese Patients. Ocul. Immunol. Inflamm [Internet]. 2018 [Acceso: 28/07/2021]; 26:387-396. Disponible en: https://doi.org/10.1080/09273948.2016.1241282
Ryu SJ, Kang MH, Seong M, Cho H, Shin YU. Anterior scleritis following intravitreal injections in a patient with rheumatoid arthritis: A case report. Medicine [Internet]. 2017 [Acceso: 28/07/2021]; 96, e8925. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5709030/
Díaz-Valle D, Sánchez RM, Espartero MF, Allen DP. Treatment of refractory anterior diffuse scleritis with infliximab. Arch. Soc. Esp. Oftalmol [Internet]. 2004 [Acceso: 28/07/2021]; 79:405-8. Disponible en: https://doi.org/10.4321/s0365-66912004000800010
Lawuyi LE, Gurbaxani A. Refractory necrotizing scleritis successfully treated with adalimumab. J. Ophthalmic Inflamm. Infect [Internet]. 2016 [Acceso: 28/07/2021]; 6(37). Disponible en: https://link.springer.com/article/10.1186/s12348-016-0107-y
Tlucek PS, Stone DU. Certolizumab Pegol Therapy for Rheumatoid Arthritis-Associated Scleritis. Cornea [Internet]. 2012 [Acceso: 28/07/2021]; 31, 90-1. Disponible en: https://journals.lww.com/corneajrnl/Abstract/2012/01000/Certolizumab_Pegol_Therapy_for_Rheumatoid.18.aspx
Durrani K, Kempen JH, Ying G-S, Kacmaz RO, Artornsombudh P, Rosenbaum JT, et al. Adalimumab for Ocular Inflammation. Ocul. Immunol. Inflamm [Internet]. 2017 [Acceso: 28/07/2021]; 25:405-12. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5033708/
Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders. Ophthalmology [Internet]. 2014 [Acceso: 28/07/2021]; 21:785-96. Disponible en: https://doi.org/10.1016/j.ophtha.2013.09.048
Fabiani C, Sota J, Sainz-de-la-Maza M, Pelegrín L, Emmi G, Lopalco G, et al. New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediat. Inflamm [Internet]. 2020[Acceso: 28/07/2021]; 8294560. Disponible en: https://www.hindawi.com/journals/mi/2020/8294560/
Schuler S, Brunner M, Bernauer W. Rituximab and Acute Retinal Necrosis in a Patient with Scleromalacia and Rheumatoid Arthritis. Ocul. Immunol. Inflamm [Internet]. 2016 [Acceso: 28/07/2021]; 24: 96-8. Disponible en: https://www.tandfonline.com/doi/full/10.3109/09273948.2014.999377
Silpa S Oray M, Preble JM, Foster CS. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol [Internet]. 2016 [Acceso: 28/07/2021]; 94, e400-e406. Disponible en: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/aos.13015
Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for Refractory Uveitis and Scleritis. Am. J. Ophthalmol [Internet]. Case Rep. 2019 [Acceso: 28/07/2021]; 13:53-5. Disponible en: https://www.sciencedirect.com/science/article/pii/S2451993618303402
Pyare R, Kaushik V, Majumder PD, Biswas J. Tofacitinib in recalcitrant scleritis: First case report from India. Indian J. Ophthalmol [Internet]. 2020 [Acceso: 28/07/2021]; 68:1988-90. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690527/
Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel A, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) Gel. Drug Des. Dev. Ther [Internet]. 2011 [Acceso: 28/07/2021]; 5:147-53. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063118/
Sohn EH, Wang R, Read R, Roufas A, Teo L, Moorthy R, et al. Long-Term, Multicenter Evaluation of Subconjunctival Injection of Triamcinolone for Non-Necrotizing, Noninfectious Anterior Scleritis. Ophthalmology [Internet]. 2011 [Acceso: 28/07/2021]; 118:1932-7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184362/
Bhatt N, Dalal M, Tucker W, Obiyor D, Nussenblatt R, Sen HN. Subconjunctival Sirolimus in the Treatment of Autoimmune Non-Necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. Am. J. Ophthalmol [Internet]. 2015 [Acceso: 28/07/2021]; 159: 601-6. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4329278/
Turesson C, O'Fallon WM, Crowson CSm Gabriel SE, Matteson EL. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J. Rheumatol [Internet]. 2002 [Acceso: 28/07/2021]; 29:62-7. Disponible en: https://www.jrheum.org/content/jrheum/29/1/62.full.pdf
Kishore S, Maher L, Majithia V. Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace. Curr. Rheumatol [Internet]. Rep. 2017 [Acceso: 28/07/2021]; 19, 39. Disponible en: https://link.springer.com/article/10.1007/s11926-017-0667-3
Kempen JH, Pistilli M, Begum H, Fitzgerald TD, Liesegang TL, Payal A, et al. Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors. Am. J. Ophthalmol [Internet]. 2019 [Acceso: 28/07/2021]; Disponible en https://doi.org/10.1016/j.ajo.2019.03.024
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
